ROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (NASDAQ: HGSI) today announced that its senior management will discuss BENLYSTA and the Phase 3 BLISS trial results during an Analyst & Investor Meeting the Company will host at the 2010 European League Against Rheumatism’s Annual European Congress of Rheumatology. The HGSI Analyst & Investor meeting will begin at approximately 9:30 AM Eastern on Thursday, June 17, 2010, and will be accessible by webcast at www.hgsi.com.
